This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
AlloVir Inc. (formerly ViraCyte; developing cell therapies for virus-associated diseases) raised $121mm through its Series B financing led by Fidelity Management and Research Co., which was joined by Gilead Sciences (adds a board observer), F2 Ventures (adds a director), Redmile Group, Invus, EcoR1 Capital, Samsara BioCapital, and Leerink Partners. AlloVir will use the proceeds for Phase III trials of its lead antiviral program Viralym-M (ALVR105).
Gene Therapy, Cell Therapy
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?